What is Spruce Bio?
Spruce Bio is a specialized biopharmaceutical enterprise dedicated to the discovery and commercialization of innovative treatments for rare endocrine disorders. The company is currently focused on the development of tildacerfont, a promising non-steroidal therapy designed to treat classic congenital adrenal hyperplasia (CAH). By targeting conditions that have lacked novel therapeutic interventions for decades, Spruce Bio occupies a unique niche in the life sciences sector. Their research also extends to addressing primary adrenal androgen excess in patients with polycystic ovary syndrome (PCOS), further diversifying their clinical portfolio and potential market impact.
How much funding has Spruce Bio raised?
Spruce Bio has raised a total of $401.6M across 7 funding rounds:
Series A
$20M
Series B
$88M
Stock Offering
$90M
Share Placement
$53.6M
Stock/Share Issuance
$50M
Private Equity
$50M
Debt
$50M
Series A (2017): $20M with participation from Novo Holdings
Series B (2020): $88M led by RiverVest Venture Partners, Novo Holdings, Rock Springs Capital LLC, Abingworth LLP, HealthCap Partners LLC, Sands Capital Management, Omega Funds, and Aisling Capital LLC
Stock Issuance/Offering (2020): $90M, investors not publicly disclosed
Share Placement (2023): $53.6M featuring Rock Springs Capital, HealthCap Partners, 5AM Ventures, RiverVest Venture Partners, Novo Holdings, Abingworth, and Armistice Capital
Stock/Share Issuance (2025): $50M, investors not publicly disclosed
Private Equity (2025): $50M, investors not publicly disclosed
Debt (2026): $50M led by Avenue Capital Group
Key Investors in Spruce Bio
Rock Springs Capital
A healthcare investment firm utilizing a research-intensive, science-first approach to identify and support innovations that address critical unmet medical needs.
HealthCap Partners
A private equity firm specializing in growth capital and strategic real estate solutions tailored to the specific needs of the healthcare industry.
5AM Ventures
A life science-focused venture capital firm that partners with founders to fund rigorous science and bring transformative therapies to patients.
What's next for Spruce Bio?
Looking ahead, the strategic deployment of the $50M will be instrumental in navigating the final stages of clinical trials and regulatory submission processes. The company is expected to prioritize the advancement of tildacerfont, aiming to provide a first-in-class solution for patients with significant unmet medical needs. As Spruce Bio transitions into a more mature phase of its lifecycle, the focus will likely shift toward scaling manufacturing capabilities and establishing commercial infrastructure. Continued support from high-conviction life science investors suggests a robust outlook for the company's long-term value creation and its potential to redefine the standard of care in endocrine medicine.
See full Spruce Bio company page
